Projects

  • Resistance under treatment in breast cancer Grant scheme: ERA-NET Programme: ERACoSysMed Acronym: RESCUER Start: 1 August 2020 End: 31 May 2024 Coordinated by University of Oslo, Institute of Basic Medical Sciences, Norway. Number of partners: 5; Funding for the BMC SAS: 120,000 €; responsible person on behalf of the BMC SAS: Marína Cihová https://www.era-learn.eu/network-information/networks/eracosysmed/3rd-joint-transnational-call-for-european-researchprojects-on-systems-medicine/resistance-under-treatment-in-breast-cancer
  • Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors Grant scheme: ERA-NET Programme: TRANSCAN-2 Acronym: NExT Start: 1 September 2019 End: 31 March 2023 Coordinated by Fraunhofer Institute for Biomedical Engineering IBMT, Germany. Number of partners: 5 Funding for the BMC SAS: 105,000 € Responsible person on behalf of the BMC SAS: Božena Smolková https://www.next-project.eu
  • Reprogramming pancreatic ductal adenocarcinoma microenvironment towards immunotherapy. APVV-21-0197 Coordinated by BMC SAS, total funding: 250,000 € Funding for the BMC SAS: 140,000€ Responsible person: Božena Smolková
  • Identification of novel biomarkers linked to the relapse of metastatic colorectal cancer after metastasectomy. APVV-21-0296 Coordinated by Comenius University in Bratislava, Faculty of Medicine in Bratislava, total funding: 249,575 € Funding for the BMC SAS: 88,342 € Responsible person on behalf of the BMC SAS: Miroslava Matúšková
  • Identification of new treatment options in refractory testicular germ cell tumors. APVV-20-0158 Acronym: REZTEST Start: 01.07.2021 End: 30.06.2025 Coordinated by Comenius University in Bratislava, Faculty of Medicine in Bratislava, total funding: 249,772 € Funding for the BMC SAS: 62 023 € Responsible person on behalf of the BMC SAS: Silvia Schmidtová
  • Suicide gene therapy mediated by mesenchymal stromal and pancreatic tumor cell-excreted extracellular vesicles in the treatment of pancreatic ductal adenocarcinoma. APVV-20-0143 Acronym: ExoTREAT Start: 01.07.2021 End: 30.06.2025 Coordinated by BMC SAS. Total funding: 250,000 € Funding for the BMC SAS: 164,000 € Responsible person on behalf of the BMC SAS: Marína Cihová
  • TArgetiNg Dna mEthylation by epigenetic editing and its implementation into personalised diagnostics and therapy of uveal Melanoma. APVV-17-0369 Acronym: TANDEM Start: 01.08.2018 End: 30.06.2022 Coordinated by BMC SAS. Total funding: 249,000 € Funding for the BMC SAS: 164,000 € Responsible person on behalf of the BMC SAS: Božena Smolková
  • Identification of chemoresistant cell populations with metastatic potential in colorectal carcinoma. VEGA 2/0050/19 Start: 1.1.2019 End: 31.12.2022; Responsible person: Miroslava Matúšková
  • Exosomes secreted by cancer cells of digestive organs, their characterization and modification by the CRISPR/Cas9 system for the aim of use in therapy. VEGA 2/0178/21 Start: 1.1.2021 End: 31.12.2024; Responsible person: Zuzana Kozovská
  • The role of mitochondria in progression of colorectal cancer. VEGA 2/0185/21 Start: 1.1.2021 End: 31.12.2024; Responsible person: Silvia Tyčiaková
  • Study of Exosome Nanoparticle Properties Secreted by Mesenchymal Stromal Cells Transduced by the HerpesSimplex Virus Thymidine Kinase (TK/HSV) Suicide Gene to Be Used for Innovative Glioblastoma Therapy. VEGA 1/0489/20 Start: 1.1.2020 End: 31.12.2022 Coordinated by Faculty of Medicine, Comenius University Bratislava Responsible person on behalf of the BMC SAS: Čestmír Altaner
  • Evaluation of the role of tumor microenvironment stromal component in breast cancer treatment outcome using an organoid model. VEGA 2/0067/22 Start: 1.1.2022 End: 31.12.2025 Coordinated by Jana Plavá
  • Unraveling the role of genetic predispositions in the context of breast cancer tumor microenvironment. VEGA 2/0138/20 Start: 1.1.2020 End: 31.12.2023 Coordinated by Marína Cihová
  • Inhibition of carbonic anhydrase IX (CA IX) circumventing cisplatin resistance in refractory testicular germ cell tumours. VEGA 1/0349/21 Start: 1.1.2021 End: 31.12.2023 Coordinated by Faculty of Medicine, Comenius University Bratislava. Responsible person on behalf of the BMC SAS: Silvia Schmidtová
  • Identification of Potential Therapeutic Targets Associated with Cisplatin Resistance in Yolk Sac Tumors. VEGA 2/0124/21 Start: 1.1.2021 End: 31.12.2024 Coordinated by Silvia Schmidtová
  • Development of patients derived xenografts models and their utilization for personalized treatment of uveal melanoma. VEGA 1/0395/21 Start: 1.1.2021 End: 31.12.2024 Coordinated by Faculty of Medicine, Comenius University Bratislava. Responsible person on behalf of the BMC SAS: Lucia Demková
  • Markers Overlapping Chemoresistance and Metastatic Potential in Colorectal Cancer – Aldehyde Dehydrogenase and Its Clinical Relevance. Grant agreement ID: 2019/60-BMCSAV-4 Funded by Ministry of Health Acronym: CAScADE Start: 1.11.2019 End: 31.12.2022 Coordinated by BMC SAS Total funding: 98,013 € Responsible person: Miroslava Matúšková
  • Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers. SAS-TUBITAK 398784; Funding body: Slovak Academy of Sciences Start: 3.9.2018 End: 30.11.2022 Coordinated by BMC SAS Total funding: 75,000 € Responsible person: Miroslava Matúšková